3-aminobenzamide has been researched along with Disease Models, Animal in 58 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concanavalin A is known to activate T cells and to cause liver injury and hepatitis, mediated in part by secretion of TNFα from macrophages." | 7.88 | 3-Aminobenzamide Prevents Concanavalin A-Induced Acute Hepatitis by an Anti-inflammatory and Anti-oxidative Mechanism. ( Aeed, H; Avni, Y; Ben-Dror, I; Ben-Nachum, I; Bernadsky, O; Biro, A; Ernst, O; Fraser, IDC; Kandhikonda, R; Katz, D; Katz, S; Lilja, A; Wardi, J; Weinstain, R; Zor, T, 2018) |
| "This study was designed to evaluate effects of hyperbaric oxygen (HBO) plus 3-aminobenzamide (3-AB) cotreatment on tissue oxidative stress parameters (TOSp), tissue histopathology scores (THSc), and bacterial translocations (Bact-Trans) in an experimental model of severe acute pancreatitis (AP)." | 7.81 | A new combination therapy in severe acute pancreatitis--hyperbaric oxygen plus 3-aminobenzamide: an experimental study. ( Aydn, S; Cinar, E; Comert, B; Deveci, MS; Inal, V; Isik, AT; Mas, MR; Mas, N; Tasci, I; Unal, MT; Yamanel, L, 2015) |
| "The anti-inflammatory activity of 3-aminobenzamide (3-AB) has been shown via histopathology and immunohistochemistry in various colitis models." | 7.80 | Effect of 3-aminobenzamide on perforation an experimental colitis model. ( Aydın, S; Cengiz, Ö; Dolapçı, M; Eroğlu, A; Menekse, E; Sepici Dinçel, A; Yıldırım, O, 2014) |
| " The aim of the present study was to examine the effects of 3-aminobenzamide (3-AB), an inhibitor of PARP activity, in the development of acute pancreatitis caused by cerulein in mice." | 7.73 | Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. ( Crisafulli, C; Cuzzocrea, S; Di Paola, R; Esposito, E; Genovese, T; Malleo, G; Mazzon, E; Meli, R; Muià, C; Sessa, E, 2006) |
| "Concanavalin A is known to activate T cells and to cause liver injury and hepatitis, mediated in part by secretion of TNFα from macrophages." | 3.88 | 3-Aminobenzamide Prevents Concanavalin A-Induced Acute Hepatitis by an Anti-inflammatory and Anti-oxidative Mechanism. ( Aeed, H; Avni, Y; Ben-Dror, I; Ben-Nachum, I; Bernadsky, O; Biro, A; Ernst, O; Fraser, IDC; Kandhikonda, R; Katz, D; Katz, S; Lilja, A; Wardi, J; Weinstain, R; Zor, T, 2018) |
| "This study was designed to evaluate effects of hyperbaric oxygen (HBO) plus 3-aminobenzamide (3-AB) cotreatment on tissue oxidative stress parameters (TOSp), tissue histopathology scores (THSc), and bacterial translocations (Bact-Trans) in an experimental model of severe acute pancreatitis (AP)." | 3.81 | A new combination therapy in severe acute pancreatitis--hyperbaric oxygen plus 3-aminobenzamide: an experimental study. ( Aydn, S; Cinar, E; Comert, B; Deveci, MS; Inal, V; Isik, AT; Mas, MR; Mas, N; Tasci, I; Unal, MT; Yamanel, L, 2015) |
| "The anti-inflammatory activity of 3-aminobenzamide (3-AB) has been shown via histopathology and immunohistochemistry in various colitis models." | 3.80 | Effect of 3-aminobenzamide on perforation an experimental colitis model. ( Aydın, S; Cengiz, Ö; Dolapçı, M; Eroğlu, A; Menekse, E; Sepici Dinçel, A; Yıldırım, O, 2014) |
| " The aim of the present study was to examine the effects of 3-aminobenzamide (3-AB), an inhibitor of PARP activity, in the development of acute pancreatitis caused by cerulein in mice." | 3.73 | Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein. ( Crisafulli, C; Cuzzocrea, S; Di Paola, R; Esposito, E; Genovese, T; Malleo, G; Mazzon, E; Meli, R; Muià, C; Sessa, E, 2006) |
| "To evaluate the effect of 3-aminobenzamide, an inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), on the long-term histologic damage in testicular ischemia-reperfusion injury." | 3.72 | Inhibition of poly(adenosine diphosphate-ribose) polymerase decreases long-term histologic damage in testicular ischemia-reperfusion injury. ( Acar, D; Akbay, E; Aktaş, S; Bozlu, M; Cayan, S; Coşkun, B; Ulusoy, E, 2004) |
| " In vivo treatment with ip administration of 3-aminobenzamide (10 mg/kg, 1 and 6 hrs after zymosan injection) or nicotinamide (50 mg/kg, 1 and 6 hrs after zymosan injection) significantly decreased mortality, inhibited the development of peritonitis, and reduced peroxynitrite formation." | 3.70 | Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. ( Caputi, AP; Costantino, G; Cuzzocrea, S; Sottile, A; Teti, D; Zingarelli, B, 1999) |
| " However, at the dosage tested in the present study, the improvement is in general moderate." | 1.43 | Effects of 3-aminobenzamide on ventricular function in infarct heart assessed by quantitative tissue velocity imaging. ( Hu, B; Pan, XQ; Shen, E; Wang, M; Zhang, YL, 2016) |
| " Exposure to PQ at toxic doses can result in fatal acute lung injury." | 1.43 | Poly-ADP-ribose polymerase inhibition provides protection against lung injury in a rat paraquat toxicity model. ( Altinel, O; Altinel, S; Ates, K; Istanbulluoglu, H; Karslioglu, Y; Korkmaz, A; Ogur, R; Topal, T; Toygar, M; Tuncer, SK; Uysal, B, 2016) |
| "After 60 min of hypothermic cardiac arrest, reperfusion was started after application of either saline vehicle (control, n = 6), or INO-1001 (1 mg/kg), a potent PARP inhibitor (n = 6)." | 1.32 | INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. ( Bährle, S; Cziráki, A; Flechtenmacher, C; Gries, A; Hagl, S; Heger, U; Mandera, S; Seres, L; Soós, P; Szabó, C; Szabó, G; Vahl, CF; Zsengellér, Z, 2004) |
| " The specific PARP inhibitor 3-aminobenzamide was injected 10 min before induction of ischemia at a dosage of 5, 10, and 20 mg/kg intracerebroventricularly." | 1.31 | The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia. ( Bardenheuer, HJ; Kopitz, J; Martin, E; Plaschke, K; Weigand, MA, 2000) |
| "Inhibiting ADP-ribosylation attenuates cerebral vasospasm after SAH in rabbits, and PARP activation may play an important role in the development of cerebral vasospasm." | 1.31 | Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits. ( Asari, S; Date, I; Iseda, K; Nakajima, M; Ninomiya, Y; Ohmoto, T; Satoh, M; Takahashi, K; Tamiya, T, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (6.90) | 18.2507 |
| 2000's | 32 (55.17) | 29.6817 |
| 2010's | 19 (32.76) | 24.3611 |
| 2020's | 3 (5.17) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Singla, S | 1 |
| Kumar, V | 1 |
| Jena, G | 1 |
| Kim, MJ | 1 |
| Moon, D | 1 |
| Jung, S | 1 |
| Lee, J | 1 |
| Kim, J | 2 |
| Ordway, GA | 1 |
| Szebeni, A | 1 |
| Hernandez, LJ | 1 |
| Crawford, JD | 1 |
| Szebeni, K | 1 |
| Chandley, MJ | 1 |
| Burgess, KC | 1 |
| Miller, C | 1 |
| Bakkalbasi, E | 1 |
| Brown, RW | 1 |
| Ieraci, A | 1 |
| Herrera, DG | 1 |
| Wardi, J | 1 |
| Ernst, O | 1 |
| Lilja, A | 1 |
| Aeed, H | 1 |
| Katz, S | 1 |
| Ben-Nachum, I | 1 |
| Ben-Dror, I | 1 |
| Katz, D | 1 |
| Bernadsky, O | 1 |
| Kandhikonda, R | 1 |
| Avni, Y | 1 |
| Fraser, IDC | 1 |
| Weinstain, R | 1 |
| Biro, A | 1 |
| Zor, T | 1 |
| Si, MK | 1 |
| Mitaka, C | 1 |
| Tulafu, M | 1 |
| Abe, S | 1 |
| Kitagawa, M | 1 |
| Ikeda, S | 1 |
| Eishi, Y | 1 |
| Kurata, S | 1 |
| Tomita, M | 1 |
| Wang, M | 1 |
| Hu, B | 1 |
| Zhang, YL | 1 |
| Shen, E | 1 |
| Pan, XQ | 1 |
| Malkoc, E | 1 |
| Alp, BF | 1 |
| Demirer, Z | 1 |
| Guragac, A | 1 |
| Dursun, F | 1 |
| Ates, F | 1 |
| Yildirim, I | 1 |
| Yuksel, R | 1 |
| Uysal, B | 3 |
| Topal, T | 2 |
| Kurt, YG | 1 |
| Ozcan, A | 1 |
| Guven, A | 2 |
| Inal, V | 1 |
| Mas, MR | 2 |
| Isik, AT | 2 |
| Comert, B | 1 |
| Aydn, S | 1 |
| Mas, N | 1 |
| Deveci, MS | 1 |
| Tasci, I | 1 |
| Yamanel, L | 1 |
| Cinar, E | 2 |
| Unal, MT | 1 |
| Yang, Z | 1 |
| Li, L | 1 |
| Chen, L | 1 |
| Yuan, W | 1 |
| Dong, L | 1 |
| Zhang, Y | 1 |
| Wu, H | 1 |
| Wang, C | 1 |
| Menekse, E | 1 |
| Aydın, S | 3 |
| Sepici Dinçel, A | 1 |
| Eroğlu, A | 1 |
| Dolapçı, M | 1 |
| Yıldırım, O | 1 |
| Cengiz, Ö | 1 |
| El-Hamoly, T | 1 |
| El-Denshary, ES | 1 |
| Saad, SM | 1 |
| El-Ghazaly, MA | 1 |
| Zhang, L | 1 |
| Yao, J | 1 |
| Wang, X | 1 |
| Li, H | 2 |
| Liu, T | 1 |
| Zhao, W | 1 |
| Meng, X | 1 |
| Song, W | 1 |
| Deng, B | 1 |
| Xing, Z | 1 |
| Zhang, W | 1 |
| Tuncer, SK | 1 |
| Altinel, S | 1 |
| Toygar, M | 1 |
| Istanbulluoglu, H | 1 |
| Ates, K | 1 |
| Ogur, R | 1 |
| Altinel, O | 1 |
| Karslioglu, Y | 1 |
| Korkmaz, A | 2 |
| Zaffini, R | 1 |
| Di Paola, R | 2 |
| Cuzzocrea, S | 4 |
| Menegazzi, M | 1 |
| Yu, X | 1 |
| Cheng, X | 1 |
| Xie, JJ | 1 |
| Liao, MY | 1 |
| Yao, R | 1 |
| Chen, Y | 2 |
| Ding, YJ | 1 |
| Tang, TT | 1 |
| Liao, YH | 1 |
| Demir, O | 1 |
| Akay, C | 1 |
| Ozyurt, M | 1 |
| Deveci, S | 1 |
| Oztas, E | 1 |
| Turk, E | 1 |
| Akgul, EO | 1 |
| Cayci, T | 1 |
| Ersoz, N | 1 |
| Joly, LM | 1 |
| Benjelloun, N | 1 |
| Plotkine, M | 3 |
| Charriaut-Marlangue, C | 2 |
| Dirlik, M | 1 |
| Caglikulekci, M | 1 |
| Cinel, I | 2 |
| Cinel, L | 1 |
| Tamer, L | 1 |
| Pata, C | 1 |
| Kanik, A | 1 |
| Ocal, K | 1 |
| Ogetman, Z | 1 |
| Darmon, D | 1 |
| Goldfarb, M | 1 |
| Shina, A | 1 |
| Rosen, S | 1 |
| Heyman, SN | 1 |
| Suh, SW | 1 |
| Aoyama, K | 1 |
| Garnier, P | 1 |
| Matsumori, Y | 1 |
| Gum, E | 1 |
| Liu, J | 2 |
| Swanson, RA | 2 |
| Gupta, S | 1 |
| Kaul, CL | 1 |
| Sharma, SS | 1 |
| Bozlu, M | 1 |
| Coşkun, B | 1 |
| Cayan, S | 1 |
| Acar, D | 1 |
| Aktaş, S | 1 |
| Ulusoy, E | 1 |
| Akbay, E | 1 |
| Yamazaki, K | 1 |
| Miwa, S | 1 |
| Ueda, K | 1 |
| Tanaka, S | 1 |
| Toyokuni, S | 1 |
| Unimonh, O | 1 |
| Nishimura, K | 1 |
| Komeda, M | 1 |
| Cole, K | 1 |
| Perez-Polo, JR | 1 |
| Koh, SH | 1 |
| Chang, DI | 1 |
| Kim, HT | 1 |
| Kim, MH | 1 |
| Kim, KS | 1 |
| Bae, I | 1 |
| Kim, H | 1 |
| Kim, DW | 1 |
| Kim, SH | 1 |
| Strosznajder, R | 1 |
| Gajkowska, B | 1 |
| Mazzon, E | 1 |
| Genovese, T | 1 |
| Muià, C | 1 |
| Crisafulli, C | 1 |
| Malleo, G | 1 |
| Esposito, E | 1 |
| Meli, R | 1 |
| Sessa, E | 1 |
| Lam, TT | 1 |
| Ugriumova, GA | 1 |
| Krasil'nikov, II | 1 |
| Alferova, OF | 1 |
| Vinogradova, ID | 1 |
| Vertiev, IV | 1 |
| Zingarelli, B | 2 |
| Caputi, AP | 2 |
| Costantino, G | 1 |
| Sottile, A | 1 |
| Teti, D | 1 |
| Nagayama, T | 1 |
| Simon, RP | 1 |
| Chen, D | 1 |
| Henshall, DC | 1 |
| Pei, W | 1 |
| Stetler, RA | 1 |
| Chen, J | 1 |
| Plaschke, K | 1 |
| Kopitz, J | 1 |
| Weigand, MA | 1 |
| Martin, E | 1 |
| Bardenheuer, HJ | 1 |
| Albertini, M | 1 |
| Clement, MG | 1 |
| Lafortuna, CL | 1 |
| Caniatti, M | 1 |
| Magder, S | 1 |
| Abdulmalek, K | 1 |
| Hussain, SN | 1 |
| Jijon, HB | 1 |
| Churchill, T | 1 |
| Malfair, D | 1 |
| Wessler, A | 1 |
| Jewell, LD | 1 |
| Parsons, HG | 1 |
| Madsen, KL | 1 |
| Satoh, M | 1 |
| Date, I | 1 |
| Nakajima, M | 1 |
| Takahashi, K | 1 |
| Iseda, K | 1 |
| Tamiya, T | 1 |
| Ohmoto, T | 1 |
| Ninomiya, Y | 1 |
| Asari, S | 1 |
| Tabuchi, K | 1 |
| Ito, Z | 1 |
| Tsuji, S | 1 |
| Nakagawa, A | 1 |
| Serizawa, F | 1 |
| Hara, A | 1 |
| Kusakari, J | 1 |
| Liaudet, L | 3 |
| Timashpolsky, L | 1 |
| Virág, L | 1 |
| Cziráki, A | 3 |
| Szabó, C | 9 |
| Boulu, RG | 1 |
| Mesenge, C | 1 |
| Verrecchia, C | 1 |
| Taner, AS | 1 |
| Ozer, L | 1 |
| Onde, U | 1 |
| Taner, D | 1 |
| Koksoy, C | 1 |
| Koedel, U | 1 |
| Winkler, F | 1 |
| Angele, B | 1 |
| Fontana, A | 1 |
| Pfister, HW | 1 |
| Cardinale, A | 1 |
| Paldino, E | 1 |
| Giampà, C | 1 |
| Bernardi, G | 1 |
| Fusco, FR | 1 |
| Toshimitsu, H | 1 |
| Yoshimoto, Y | 1 |
| Augustine, CK | 1 |
| Padussis, JC | 1 |
| Yoo, JS | 1 |
| Angelica Selim, M | 1 |
| Pruitt, SK | 1 |
| Friedman, HS | 1 |
| Ali-Osman, F | 1 |
| Tyler, DS | 1 |
| d'Avila, JC | 1 |
| Lam, TI | 1 |
| Bingham, D | 1 |
| Shi, J | 1 |
| Won, SJ | 1 |
| Kauppinen, TM | 1 |
| Massa, S | 1 |
| Choi, SK | 1 |
| Galán, M | 1 |
| Kassan, M | 1 |
| Partyka, M | 1 |
| Trebak, M | 1 |
| Matrougui, K | 1 |
| Szabó, G | 2 |
| Soós, P | 1 |
| Mandera, S | 1 |
| Heger, U | 1 |
| Flechtenmacher, C | 1 |
| Bährle, S | 1 |
| Seres, L | 1 |
| Gries, A | 1 |
| Zsengellér, Z | 3 |
| Vahl, CF | 1 |
| Hagl, S | 1 |
| Pacher, P | 2 |
| Vaslin, A | 1 |
| Benko, R | 1 |
| Mabley, JG | 2 |
| Haskó, G | 2 |
| Marton, A | 1 |
| Bátkai, S | 1 |
| Kollai, M | 1 |
| Besson, VC | 1 |
| Marchand-Verrecchia, C | 1 |
| Farivar, AS | 1 |
| McCourtie, AS | 1 |
| MacKinnon-Patterson, BC | 1 |
| Woolley, SM | 1 |
| Barnes, AD | 1 |
| Chen, M | 2 |
| Jagtap, P | 1 |
| Salerno, CT | 1 |
| Mulligan, MS | 1 |
| Kendirci, M | 1 |
| Bivalacqua, TJ | 1 |
| Gur, S | 1 |
| Usta, MF | 1 |
| Hellstrom, WJ | 1 |
| Beller, CJ | 1 |
| Radovits, T | 1 |
| Kosse, J | 1 |
| Gerö, D | 1 |
| Hauser, B | 1 |
| Gröger, M | 1 |
| Ehrmann, U | 1 |
| Albicini, M | 1 |
| Brückner, UB | 1 |
| Schelzig, H | 1 |
| Venkatesh, B | 1 |
| Speit, G | 1 |
| Radermacher, P | 1 |
| Kick, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardia[NCT00271765] | Phase 2 | 40 participants | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 3-aminobenzamide and Disease Models, Animal
| Article | Year |
|---|---|
Neuronal trauma model: in search of Thanatos.
Topics: Animals; Apoptosis; Benzamides; Disease Models, Animal; DNA Damage; Energy Metabolism; Humans; Neuro | 2004 |
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase].
Topics: Animals; Apoptosis; Benzamides; Brain Ischemia; Disease Models, Animal; DNA Damage; Gene Deletion; H | 2001 |
56 other studies available for 3-aminobenzamide and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
3-aminobenzamide protects against colitis associated diabetes mellitus in male BALB/c mice: Role of PARP-1, NLRP3, SIRT-1, AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Colitis; Colitis, Ulcerative; Colon; Diabetes Mellitus; Dise | 2023 |
Cisplatin nephrotoxicity is induced via poly(ADP-ribose) polymerase activation in adult zebrafish and mice.
Topics: Animals; Benzamides; Cisplatin; Disease Models, Animal; DNA Damage; Kidney Diseases; Kidney Tubules; | 2020 |
Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models.
Topics: Animals; Antidepressive Agents; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug | 2017 |
Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.
Topics: Animals; Animals, Newborn; Benzamides; Caspase 3; Cell Death; Central Nervous System Depressants; Ce | 2018 |
3-Aminobenzamide Prevents Concanavalin A-Induced Acute Hepatitis by an Anti-inflammatory and Anti-oxidative Mechanism.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Antioxidants; Benzamides; Cells, Cultured; Concana | 2018 |
Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats.
Topics: Animals; Benzamides; Creatinine; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Kidney; Lacta | 2013 |
Effects of 3-aminobenzamide on ventricular function in infarct heart assessed by quantitative tissue velocity imaging.
Topics: Animals; Benzamides; Disease Models, Animal; Echocardiography; Female; Linear Models; Myocardial Inf | 2016 |
Efficacy of poly(adenosine diphosphate-ribose) polymerase inhibition in extracorporeal shock wave-induced renal injury.
Topics: Acute Kidney Injury; Animals; Benzamides; Disease Models, Animal; Drug Evaluation, Preclinical; Glut | 2014 |
A new combination therapy in severe acute pancreatitis--hyperbaric oxygen plus 3-aminobenzamide: an experimental study.
Topics: Acute Disease; Animals; Bacterial Translocation; Benzamides; Combined Modality Therapy; Disease Mode | 2015 |
PARP-1 mediates LPS-induced HMGB1 release by macrophages through regulation of HMGB1 acetylation.
Topics: Acetylation; Acetylcysteine; Animals; Benzamides; Cell Nucleus; Cytoplasm; Disease Models, Animal; E | 2014 |
Effect of 3-aminobenzamide on perforation an experimental colitis model.
Topics: Animals; Benzamides; Colitis; Colon; Disease Models, Animal; Enzyme Inhibitors; Intestinal Perforati | 2014 |
3-aminobenzamide, a poly (ADP ribose) polymerase inhibitor, enhances wound healing in whole body gamma irradiated model.
Topics: Animals; Benzamides; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gamma Ray | 2015 |
Poly (ADP-ribose) synthetase inhibitor has a heart protective effect in a rat model of experimental sepsis.
Topics: Animals; Apoptosis; Benzamides; Disease Models, Animal; Heart; Immunohistochemistry; Male; Microscop | 2015 |
3-aminobenzamide, one of poly(ADP-ribose)polymerase-1 inhibitors, rescuesapoptosisin rat models of spinal cord injury.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Benzamides; Caspase 3; Disease Models, Animal; Humans | 2015 |
Poly-ADP-ribose polymerase inhibition provides protection against lung injury in a rat paraquat toxicity model.
Topics: Animals; Antioxidants; Benzamides; Biomarkers; Disease Models, Animal; Female; Injections, Intraperi | 2016 |
PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.
Topics: Airway Remodeling; Animals; Anti-Asthmatic Agents; Asthma; Benzamides; Bronchoalveolar Lavage Fluid; | 2016 |
Poly (ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by hyperhomocysteinemia in rats.
Topics: Animals; Aorta, Thoracic; Benzamides; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; E | 2009 |
Does the 3-aminobenzamide effect on bacterial translocation affect experimental acute necrotizing pancreatitis?
Topics: Animals; Bacterial Translocation; Benzamides; Cholagogues and Choleretics; Disease Models, Animal; E | 2009 |
3-aminobenzamide, a poly ADP ribose polymerase inhibitor, attenuates renal ischemia/reperfusion injury.
Topics: Animals; Benzamides; Blood Chemical Analysis; Blood Urea Nitrogen; Creatinine; Disease Models, Anima | 2009 |
Distribution of Poly(ADP-ribosyl)ation and cell death after cerebral ischemia in the neonatal rat.
Topics: Animals; Animals, Newborn; Benzamides; Brain Ischemia; Cell Death; Disease Models, Animal; Female; M | 2003 |
The effect of PARS inhibition on ileal histopathology, apoptosis and lipid peroxidation in LPS-induced obstructive jaundice.
Topics: Adenosine Triphosphatases; Analysis of Variance; Animals; Apoptosis; Benzamides; Disease Models, Ani | 2003 |
Effect of poly(ADP-ribose) polymerase inhibition on outer medullary hypoxic damage.
Topics: Acute Kidney Injury; Animals; Benzamides; Contrast Media; Disease Models, Animal; Disease Progressio | 2003 |
Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia.
Topics: Animals; Astrocytes; Behavior, Animal; Benzamides; Benzopyrans; Cell Death; Cells, Cultured; Cogniti | 2003 |
Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats.
Topics: Animals; Antioxidants; Benzamides; Brain Ischemia; Disease Models, Animal; Drug Combinations; Drug T | 2004 |
Inhibition of poly(adenosine diphosphate-ribose) polymerase decreases long-term histologic damage in testicular ischemia-reperfusion injury.
Topics: Animals; Benzamides; Biopsy; Dimethyl Sulfoxide; Disease Models, Animal; Humans; Male; Poly(ADP-ribo | 2004 |
Prevention of myocardial reperfusion injury by poly(ADP-ribose) synthetase inhibitor, 3-aminobenzamide, in cardioplegic solution: in vitro study of isolated rat heart model.
Topics: Animals; Apoptosis; Benzamides; Cardiac Surgical Procedures; Cardioplegic Solutions; Disease Models, | 2004 |
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.
Topics: Animals; Benzamides; Brain; Brain Ischemia; Disease Models, Animal; Matrix Metalloproteinase 9; NF-k | 2005 |
Effect of 3-aminobenzamide on Bcl-2, Bax and AIF localization in hippocampal neurons altered by ischemia-reperfusion injury. the immunocytochemical study.
Topics: Animals; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Benzamides; Disease Models, Animal; | 2006 |
Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein.
Topics: Acute Disease; Animals; Benzamides; Ceruletide; Disease Models, Animal; Enzyme Inhibitors; Immunohis | 2006 |
The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemia/reperfusion damage in rat retina.
Topics: Animals; Apoptosis; Benzamides; Disease Models, Animal; DNA Fragmentation; Dose-Response Relationshi | 1997 |
[Activity of benzamide and it's derivatives against botulinum intoxication].
Topics: Animals; Antiviral Agents; Benzamides; Botulinum Toxins, Type A; Botulism; Disease Models, Animal; E | 1997 |
Peroxynitrate-mediated DNA strand breakage activates poly(ADP-ribose) synthetase and causes cellular energy depletion in a nonseptic shock model induced by zymosan in the rat.
Topics: Animals; Benzamides; Disease Models, Animal; DNA Damage; Energy Metabolism; Enzyme Activation; Macro | 1998 |
Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat.
Topics: Animals; Benzamides; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Male; Multip | 1999 |
Activation of poly(ADP-ribose) polymerase in the rat hippocampus may contribute to cellular recovery following sublethal transient global ischemia.
Topics: Animals; Benzamides; Blotting, Northern; Blotting, Western; Cell Death; Cell Survival; Disease Model | 2000 |
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Topics: Animals; Arterial Occlusive Diseases; Benzamides; Brain Ischemia; Carotid Artery, Common; Cerebral C | 2000 |
Role of poly-(ADP-ribose) synthetase in lipopolysaccharide-induced vascular failure and acute lung injury in pigs.
Topics: Animals; Benzamides; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Enzyme Inhibitors; Escher | 2000 |
Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis.
Topics: Animals; Benzamides; Chronic Disease; Colitis; Disease Models, Animal; Energy Metabolism; Enzyme Inh | 2000 |
Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Topics: Animals; Basilar Artery; Benzamides; Cerebral Angiography; Disease Models, Animal; Endothelium, Vasc | 2001 |
Poly(adenosine diphosphate-ribose) synthetase inhibitor 3-aminobenzamide alleviates cochlear dysfunction induced by transient ischemia.
Topics: Action Potentials; Analysis of Variance; Animals; Auditory Threshold; Benzamides; Blood Flow Velocit | 2001 |
Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.
Topics: Animals; Benzamides; Creatine Kinase; Disease Models, Animal; Enzyme Activation; Heart; Hemodynamics | 2001 |
Poly(adp-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge.
Topics: Animals; Bacterial Translocation; Benzamides; Colony-Forming Units Assay; Disease Models, Animal; En | 2001 |
Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase.
Topics: Animals; Benzamides; Brain; Brain Chemistry; Cell Line; Central Nervous System Diseases; Disease Mod | 2002 |
PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
Topics: Animals; Blotting, Western; Body Weight; Brain-Derived Neurotrophic Factor; Corpus Striatum; Cyclic | 2015 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarb | 2010 |
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor.
Topics: Analysis of Variance; Animals; Brain Injuries; CD11b Antigen; Cell Survival; Cerebral Cortex; Diseas | 2012 |
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Topics: Animals; Benzimidazoles; Blood Glucose; Blood Pressure Determination; Blotting, Western; Body Weight | 2012 |
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Topics: Acetylcholine; Adenosine Diphosphate Ribose; Animals; Disease Models, Animal; Dogs; Enzyme Inhibitor | 2004 |
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging.
Topics: Aging; Animals; Disease Models, Animal; Enzyme Inhibitors; Heart Diseases; Heart Function Tests; Ind | 2004 |
Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat.
Topics: Animals; Brain; Brain Injuries; Collagen Type XI; Disease Models, Animal; Enzyme Inhibitors; Immunoh | 2005 |
Poly (ADP) ribose polymerase inhibition improves rat cardiac allograft survival.
Topics: Animals; Cyclosporine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2005 |
Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury.
Topics: Adenosine Diphosphate Ribose; Analysis of Variance; Animals; Biopsy, Needle; Disease Models, Animal; | 2005 |
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Doxorubicin; Enzyme Inhibitors; Heart Diseases; I | 2006 |
Activation of the peroxynitrite-poly(adenosine diphosphate-ribose) polymerase pathway during neointima proliferation: a new target to prevent restenosis after endarterectomy.
Topics: Adenosine Diphosphate Ribose; Animals; Biopsy, Needle; Carotid Stenosis; Constriction, Pathologic; D | 2006 |
The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion.
Topics: Animals; Aorta, Thoracic; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; DNA Damage; | 2006 |